PDCD1 and neoplasm: Notably, while the combination of C215Fab-SEA with anti-PD-1 treatment showed a synergistic effect in tumor growth inhibition, overall survival and tumor free rates, the superiority of the combination therapy over C215Fab-SEA monotherapy was less evident in the immune profiling results.